Ultra-low doses of microARNs restore a strong immune response in patients with Chronic Active Epstein-Barr Virus infection (CAEBV)

Abstract

Chronic active Epstein-Barr Virus infection (CAEBV) is an abnormal response of the immune system to EBV infection, characterized by the absence of anti-EBNA (EBV Nuclear Antigens) IgG and associated with chronic fatigue and several immune related diseases. We present here an innovative therapeutic approach of CAEBV based on the use of ultra-low doses of non-coding RNAs (ncRNAs) involved in the host-virus interaction. We performed a retrospective study on 26 patients treated with our remedy. All the patients expect one developed positive EBNA IgG within eighteen months of starting treatment. Among the 25 cases that seroconverted, 75% report a significant improvement of their symptoms, especial of chronic fatigue. This study gives the proof of the efficiency of ultra-low doses of ncRNAs in restoring a strong immune response against EBV. More generally, this therapeutic approach can potentially be used in almost all pathologies.